Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.3 USD | +1.29% | +0.83% | -51.41% |
Financials (USD)
Sales 2024 * | 954M | Sales 2025 * | 1.07B | Capitalization | 2.49B |
---|---|---|---|---|---|
Net income 2024 * | 101M | Net income 2025 * | 205M | EV / Sales 2024 * | 2.02 x |
Net cash position 2024 * | 570M | Net cash position 2025 * | 786M | EV / Sales 2025 * | 1.6 x |
P/E ratio 2024 * |
26.3
x | P/E ratio 2025 * |
13.2
x | Employees | 610 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.52% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | +0.67% | ||
1 week | -0.66% | ||
1 month | -11.59% | ||
3 months | -37.11% | ||
6 months | -33.19% | ||
Current year | -51.77% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | -.--% | - | |
1.24% | 14 M€ | -5.07% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 15.21 | +0.73% | 777 080 |
24-05-31 | 15.1 | +0.67% | 1,342,842 |
24-05-30 | 15 | +2.60% | 1,133,505 |
24-05-29 | 14.62 | -3.11% | 1,388,763 |
24-05-28 | 15.09 | -0.72% | 1,059,072 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.77% | 2.49B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- ACAD Stock